# Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

> **NCT00070291** · PHASE2 · TERMINATED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT00070291
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01-24
- **Primary completion:** 2009-03
- **Final completion:** 2011-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070291, "Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00070291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*